Product
LCB84
1 clinical trial
1 indication
Indication
CancerClinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-01-01